English 
Español
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody.
Related Articles
-
UDIBI
November 8, 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and without an immunomodulator...
-
-
UDIBI
An international comparative analysis and roadmap to sustainable biosimilar markets. SHOW MORE
-
UDIBI
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
-
UDIBI
Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis. SHOW MORE
-
UDIBI
Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons. SHOW MORE
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
-
UDIBI
October 6, 2021 Increased survival in puppies affected by Canine Parvovirus type II using an immunomodulator as a therapeutic...
0 Comments
